Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

After publication of the original article [1], we were notified that an author’s surname has been erroneously spelled. Elisabetta Maragoni’s family name should be replaced with Marangoni.

Bibliographic Details
Main Authors: Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Marangoni, Lesley-Ann Martin
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Breast Cancer Research
Online Access:https://doi.org/10.1186/s13058-020-1254-5

Internet

https://doi.org/10.1186/s13058-020-1254-5

Similar Items